1a4q › Citations

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.

Taylor NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J
J Med Chem 41 798-807 (1998)
Related entries: 1a4g, 1bji, 1nsb

Cited: 86 times
EuropePMC logo PMID: 9526556

Abstract

The first paper in this series (see previous article) described structure-activity studies of carboxamide analogues of zanamivir binding to influenza virus sialidase types A and B and showed that inhibitory activity of these compounds was much greater against influenza A enzyme. To understand the large differences in affinities, a number of protein-ligand complexes have been investigated using crystallography and molecular dynamics. The crystallographic studies show that the binding of ligands containing tertiary amide groups is accompanied by the formation of an intramolecular planar salt bridge between two amino acid residues in the active site of the enzyme. It is proposed that the unexpected strong binding of these inhibitors is a result of the burial of hydrophobic surface area and salt-bridge formation in an environment of low dielectric. In sialidase from type A virus, binding of the carboxamide moeity and salt-bridge formation have only a minor effect on the positions of the surrounding residues, whereas in type B enzyme, significant distortion of the protein is observed. The results suggest that the decreased affinity in enzyme from influenza B is directly correlated with the small changes that occur in the amino acid residue interactions accompanying ligand binding. Molecular dynamics calculations have shown that the tendency for salt-bridge formation is greater in influenza A sialidase than influenza B sialidase and that this tendency is a useful descriptor for the prediction of inhibitor potency.

Articles - 1a4q mentioned but not cited (10)

  1. Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes. Rueda M, Bottegoni G, Abagyan R. J Chem Inf Model 49 716-725 (2009)
  2. Rapid flexible docking using a stochastic rotamer library of ligands. Ding F, Yin S, Dokholyan NV. J Chem Inf Model 50 1623-1632 (2010)
  3. Predicting the accuracy of protein-ligand docking on homology models. Bordogna A, Pandini A, Bonati L. J Comput Chem 32 81-98 (2011)
  4. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE). Bottegoni G, Kufareva I, Totrov M, Abagyan R. J Comput Aided Mol Des 22 311-325 (2008)
  5. Binding-site assessment by virtual fragment screening. Huang N, Jacobson MP. PLoS One 5 e10109 (2010)
  6. Identification of protein-ligand binding sites by the level-set variational implicit-solvent approach. Guo Z, Li B, Cheng LT, Zhou S, McCammon JA, Che J. J Chem Theory Comput 11 753-765 (2015)
  7. Getting Docking into Shape Using Negative Image-Based Rescoring. Kurkinen ST, Lätti S, Pentikäinen OT, Postila PA. J Chem Inf Model 59 3584-3599 (2019)
  8. Fragment-based docking: development of the CHARMMing Web user interface as a platform for computer-aided drug design. Pevzner Y, Frugier E, Schalk V, Caflisch A, Woodcock HL. J Chem Inf Model 54 2612-2620 (2014)
  9. Development and validation of an improved algorithm for overlaying flexible molecules. Taylor R, Cole JC, Cosgrove DA, Gardiner EJ, Gillet VJ, Korb O. J Comput Aided Mol Des 26 451-472 (2012)
  10. Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection. Olasunkanmi OI, Mageto J, Avala Ntsigouaye J, Yi M, Fei Y, Chen Y, Chen S, Xu W, Lin L, Zhao W, Wang Y, Zhong ZH. Front Microbiol 13 875485 (2022)


Reviews citing this publication (15)

  1. A medicinal chemist's guide to molecular interactions. Bissantz C, Kuhn B, Stahl M. J Med Chem 53 5061-5084 (2010)
  2. Implications of protein flexibility for drug discovery. Teague SJ. Nat Rev Drug Discov 2 527-541 (2003)
  3. Rational approaches to improving selectivity in drug design. Huggins DJ, Sherman W, Tidor B. J Med Chem 55 1424-1444 (2012)
  4. Medical management of influenza infection. Moscona A. Annu Rev Med 59 397-413 (2008)
  5. Efficient incorporation of protein flexibility and dynamics into molecular docking simulations. Lill MA. Biochemistry 50 6157-6169 (2011)
  6. New antivirals and drug resistance. Colman PM. Annu Rev Biochem 78 95-118 (2009)
  7. Development of effective anti-influenza drugs: congeners and conjugates - a review. Shie JJ, Fang JM. J Biomed Sci 26 84 (2019)
  8. Multi-dimensional QSAR in drug discovery. Lill MA. Drug Discov Today 12 1013-1017 (2007)
  9. Neuraminidase inhibitors as anti-influenza virus agents. Kim CU, Chen X, Mendel DB. Antivir Chem Chemother 10 141-154 (1999)
  10. Directed evolution of aldolases for exploitation in synthetic organic chemistry. Bolt A, Berry A, Nelson A. Arch Biochem Biophys 474 318-330 (2008)
  11. Antivirals Targeting the Neuraminidase. Gubareva L, Mohan T. Cold Spring Harb Perspect Med 12 a038455 (2022)
  12. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Cheng CK, Tsai CH, Shie JJ, Fang JM. Future Med Chem 6 757-774 (2014)
  13. New light for science: synchrotron radiation in structural medicine. Sorensen TL, McAuley KE, Flaig R, Duke EM. Trends Biotechnol 24 500-508 (2006)
  14. Prioritizing the proteome: identifying pharmaceutically relevant targets. Swindells MB, Overington JP. Drug Discov Today 7 516-521 (2002)
  15. Zwitterionic structures: from physicochemical properties toward computer-aided drug designs. Yang Z, Li Q, Yang G. Future Med Chem 8 2245-2262 (2016)

Articles citing this publication (61)

  1. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Gubareva LV, Webster RG, Hayden FG. Antimicrob Agents Chemother 45 3403-3408 (2001)
  2. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. PLoS One 5 e12029 (2010)
  3. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM. Structure 6 735-746 (1998)
  4. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, Chand P, Kotian PL, Dehghani A, El-Kattan Y, Lin T, Hutchison TL, Montgomery JA, Kellog DL, Babu YS. Antimicrob Agents Chemother 45 1162-1167 (2001)
  5. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. PLoS Pathog 7 e1002249 (2011)
  6. Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Zhu X, Yang H, Guo Z, Yu W, Carney PJ, Li Y, Chen LM, Paulson JC, Donis RO, Tong S, Stevens J, Wilson IA. Proc Natl Acad Sci U S A 109 18903-18908 (2012)
  7. Synthesis of halogen derivatives of benzo[h]chromene and benzo[a]anthracene with promising antimicrobial activities. Khafagy MM, Abd el-Wahab AH, Eid FA, el-Agrody AM. Farmaco 57 715-722 (2002)
  8. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL. J Med Chem 53 6421-6431 (2010)
  9. Analysis of inhibitor binding in influenza virus neuraminidase. Smith BJ, Colman PM, Von Itzstein M, Danylec B, Varghese JN. Protein Sci 10 689-696 (2001)
  10. Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities. Li J, Zheng M, Tang W, He PL, Zhu W, Li T, Zuo JP, Liu H, Jiang H. Bioorg Med Chem Lett 16 5009-5013 (2006)
  11. Implementation and evaluation of a docking-rescoring method using molecular footprint comparisons. Balius TE, Mukherjee S, Rizzo RC. J Comput Chem 32 2273-2289 (2011)
  12. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Du QS, Wang SQ, Chou KC. Biochem Biophys Res Commun 362 525-531 (2007)
  13. A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches. Shepphird JK, Clark RD. J Comput Aided Mol Des 20 763-771 (2006)
  14. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Baum EZ, Wagaman PC, Ly L, Turchi I, Le J, Bucher D, Bush K. Antiviral Res 59 13-22 (2003)
  15. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M. J Mol Biol 293 1107-1119 (1999)
  16. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. Birch L, Murray CW, Hartshorn MJ, Tickle IJ, Verdonk ML. J Comput Aided Mol Des 16 855-869 (2002)
  17. Utilizing experimental data for reducing ensemble size in flexible-protein docking. Xu M, Lill MA. J Chem Inf Model 52 187-198 (2012)
  18. Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds. Lu Y, Gervay-Hague J. Carbohydr Res 342 1636-1650 (2007)
  19. In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase. Li C, Fang JS, Lian WW, Pang XC, Liu AL, Du GH. Chem Biol Drug Des 85 427-438 (2015)
  20. Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay. Hariono M, Abdullah N, Damodaran KV, Kamarulzaman EE, Mohamed N, Hassan SS, Shamsuddin S, Wahab HA. Sci Rep 6 38692 (2016)
  21. Scoring ensembles of docked protein:ligand interactions for virtual lead optimization. Paulsen JL, Anderson AC. J Chem Inf Model 49 2813-2819 (2009)
  22. Hydrophobic benzoic acids as inhibitors of influenza neuraminidase. Atigadda VR, Brouillette WJ, Duarte F, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck E, Finley J, Air GM, Luo M, Laver GW. Bioorg Med Chem 7 2487-2497 (1999)
  23. Comment Structural biology: antiviral drugs fit for a purpose. Luo M. Nature 443 37-38 (2006)
  24. Structure-guided saturation mutagenesis of N-acetylneuraminic acid lyase for the synthesis of sialic acid mimetics. Williams GJ, Woodhall T, Nelson A, Berry A. Protein Eng Des Sel 18 239-246 (2005)
  25. Zanamivir: an influenza virus neuraminidase inhibitor. Colman PM. Expert Rev Anti Infect Ther 3 191-199 (2005)
  26. Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study. Yang Z, Yang G, Zhou L. J Comput Aided Mol Des 27 935-950 (2013)
  27. Neuraminidase inhibitors as antivirals. Colman PM. Vaccine 20 Suppl 2 S55-8 (2002)
  28. Saturation transfer difference (STD) 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase. Haselhorst T, Wilson JC, Thomson RJ, McAtamney S, Menting JG, Coppel RL, von Itzstein M. Proteins 56 346-353 (2004)
  29. Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone. Smith PW, Robinson JE, Evans DN, Sollis SL, Howes PD, Trivedi N, Bethell RC. Bioorg Med Chem Lett 9 601-604 (1999)
  30. Solvent interaction energy calculations on molecular dynamics trajectories: increasing the efficiency using systematic frame selection. Lill MA, Thompson JJ. J Chem Inf Model 51 2680-2689 (2011)
  31. Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors. Yi X, Guo Z, Chu FM. Bioorg Med Chem 11 1465-1474 (2003)
  32. Synergy between combinatorial chemistry and de novo design. Leach AR, Bryce RA, Robinson AJ. J Mol Graph Model 18 358-67, 526 (2000)
  33. Inhibition of neuraminidase with neuraminic acid C-glycosides. Wang Q, Wolff M, Polat T, Du Y, Linhardt RJ. Bioorg Med Chem Lett 10 941-944 (2000)
  34. Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides. Wyatt PG, Coomber BA, Evans DN, Jack TI, Fulton HE, Wonacott AJ, Colman P, Varghese J. Bioorg Med Chem Lett 11 669-673 (2001)
  35. Synthesis and evaluation of a new series of substituted acyl(thio)urea and thiadiazolo [2,3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase. Sun C, Zhang X, Huang H, Zhou P. Bioorg Med Chem 14 8574-8581 (2006)
  36. Creation of a tailored aldolase for the parallel synthesis of sialic acid mimetics. Woodhall T, Williams G, Berry A, Nelson A. Angew Chem Int Ed Engl 44 2109-2112 (2005)
  37. CONFIRM: connecting fragments found in receptor molecules. Thompson DC, Denny RA, Nilakantan R, Humblet C, Joseph-McCarthy D, Feyfant E. J Comput Aided Mol Des 22 761-772 (2008)
  38. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry. Worrall EE, Sudarisman, Priadi A. Vaccine 27 4161-4168 (2009)
  39. The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism. Liu Y, Yang Y, Fan J, He R, Luo M, Zheng X. J Biol Chem 290 9141-9149 (2015)
  40. Unsaturated N-acetyl- D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase. Mann MC, Islam T, Dyason JC, Florio P, Trower CJ, Thomson RJ, von Itzstein M. Glycoconj J 23 127-133 (2006)
  41. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase. Sun J, Cai S, Mei H, Li J, Yan N, Wang Y. J Mol Model 16 1809-1818 (2010)
  42. One-bead-one-inhibitor-one-substrate screening of neuraminidase activity. Ying L, Gervay-Hague J. Chembiochem 6 1857-1865 (2005)
  43. Synthesis and Biological Evaluation of Non-Hydrolizable 1,2,3-Triazole Linked Sialic Acid Derivatives as Neuraminidase Inhibitors. Weïwer M, Chen CC, Kemp MM, Linhardt RJ. European J Org Chem 2009 (2009)
  44. Synthesis of screening substrates for the directed evolution of sialic acid aldolase: towards tailored enzymes for the preparation of influenza A sialidase inhibitor analogues. Woodhall T, Williams G, Berry A, Nelson A. Org Biomol Chem 3 1795-1800 (2005)
  45. Perspective: On the relevance of slower-than-femtosecond time scales in chemical structural-dynamics studies. Coppens P. Struct Dyn 2 020901 (2015)
  46. Antimicrobial activity of new 4,6-disubstituted pyrimidine, pyrazoline, and pyran derivatives. Ramiz MM, El-Sayed WA, El-Tantawy AI, Abdel-Rahman AA. Arch Pharm Res 33 647-654 (2010)
  47. Design, Microwave-Assisted Synthesis and In Silico Prediction Study of Novel Isoxazole Linked Pyranopyrimidinone Conjugates as New Targets for Searching Potential Anti-SARS-CoV-2 Agents. Algethami FK, Cherif M, Jlizi S, Ben Hamadi N, Romdhane A, Elamin MR, Alghamdi MA, Ben Jannet H. Molecules 26 6103 (2021)
  48. Development and testing of a de novo drug-design algorithm. Pellegrini E, Field MJ. J Comput Aided Mol Des 17 621-641 (2003)
  49. Quantitative Assessment of Chirality of Protein Secondary Structures and Phenylalanine Peptide Nanotubes. Sidorova A, Bystrov V, Lutsenko A, Shpigun D, Belova E, Likhachev I. Nanomaterials (Basel) 11 3299 (2021)
  50. Synthesis, Reactions and Evaluation of the Antimicrobial Activity of Some 4-(p-Halophenyl)-4H-naphthopyran, Pyranopyrimidine and Pyranotriazolopyrimidine Derivatives. Abd El-Wahab AH. Pharmaceuticals (Basel) 5 745-757 (2012)
  51. Prediction of Certain Well-Characterized Domains of Known Functions within the PE and PPE Proteins of Mycobacteria. Sultana R, Tanneeru K, Kumar AB, Guruprasad L. PLoS One 11 e0146786 (2016)
  52. Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. Li Y, Zhou B, Wang R. J Mol Graph Model 28 203-219 (2009)
  53. The importance of molecular complexity in the design of screening libraries. Nilar SH, Ma NL, Keller TH. J Comput Aided Mol Des 27 783-792 (2013)
  54. A molecular evolution algorithm for ligand design in DOCK. Prentis LE, Singleton CD, Bickel JD, Allen WJ, Rizzo RC. J Comput Chem 43 1942-1963 (2022)
  55. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase. Sun J, Cai S, Mei H, Li J, Yan N, Wang Q, Lin Z, Huo D. Chem Biol Drug Des 76 245-254 (2010)
  56. Regioselective synthesis of 4azido-Neu2en5,7Ac(2)1Me and its intramolecular transformation to 4azido-Neu2en5,9Ac(2)1Me. Zhao Q, Lou Y, Xiong R, Li H, Shen J. Carbohydr Res 343 2459-2462 (2008)
  57. Using common spatial distributions of atoms to relate functionally divergent influenza virus N10 and N11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains. Weininger A, Weininger S. PLoS One 10 e0117499 (2015)
  58. Early days in drug discovery by crystallography - personal recollections. Colman PM. Acta Crystallogr A 69 60-62 (2013)
  59. Microwave assisted the short time clean synthesis of 1,3-diketones as building blocks in heterocyclic synthesis: a facile synthesis and antimicrobial evaluation of new dihydropyridine, 4H-pyrane, dihydropyridazine, pyrimidine and pyrazole derivatives. Abdel Reheim MAM, Abdel Hafiz IS, Abdel Rady HSE. Mol Divers 26 741-755 (2022)
  60. Synthesis and antitumor activity against HepG-2, PC-3, and HCT-116 cells of some naphthyridine and pyranopyridinecarbonitrile derivatives. Mohamed SF, Abdel-Hafez NA, Amr AE, Awad HM. Russ J Gen Chem 87 1264-1274 (2017)
  61. Vitisin B inhibits influenza A virus replication by multi-targeting neuraminidase and virus-induced oxidative stress. Kwon EB, Li W, Kim YS, Kim B, Chung HS, Go Y, Ko HJ, Song JH, Kim YH, Choi CW, Choi JG. Acta Pharm Sin B 13 174-191 (2023)


Related citations provided by authors (2)

  1. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.. Burmeister WP, Ruigrok RW, Cusack S EMBO J 11 49-56 (1992)
  2. Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase.. Burmeister WP, Daniels RS, Dayan S, Gagnon J, Cusack S, Ruigrok RW Virology 180 266-72 (1991)

Quick links